This differentiation block will not stand, man: ivosidenib for MDS

Blood Adv. 2024 Aug 13;8(15):4207-4208. doi: 10.1182/bloodadvances.2024013427.

Authors

Ryan J Beechinor^{1

2}, Brian A Jonas³

Affiliations

¹ Department of Pharmacy, University of California Davis Medical Center, Sacramento, CA.
² University of California, San Francisco School of Pharmacy, San Francisco, CA.
³ Division of Malignant Hematology/Cellular Therapy and Transplantation, Department of Internal Medicine, University of California Davis School of Medicine, Sacramento, CA.

No abstract available

Publication types

Comment

MeSH terms

Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use
Cell Differentiation / drug effects
Glycine* / analogs & derivatives
Glycine* / pharmacology
Glycine* / therapeutic use
Humans
Myelodysplastic Syndromes* / drug therapy
Pyridines* / pharmacology
Pyridines* / therapeutic use

Substances

Pyridines
Glycine
ivosidenib
Antineoplastic Agents